Are you Dr. Morganroth?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 48 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
1040 Stony Ln
Gladwyne, PA 19035Phone+1 215-840-4961Fax+1 610-527-0295
Summary
- Dr. Joel Morganroth, MD is a cardiologist in Gladwyne, Pennsylvania. He is currently licensed to practice medicine in Pennsylvania, New York, and Delaware. He is affiliated with Penn Presbyterian Medical Center.
Education & Training
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1970 - 1972
University of Michigan Medical SchoolClass of 1970
Certifications & Licensure
FL State Medical License 1973 - 2025
PA State Medical License 1974 - 2024
CA State Medical License 1971 - 2021
DE State Medical License 1987 - 2015
MA State Medical License 1970 - 2011
MI State Medical License 1971 - 2010
NJ State Medical License 1977 - 2009- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Cardiovascular Disease
- Join now to see all
Awards, Honors, & Recognition
- Fellow (FACC) American College of Cardiology
Clinical Trials
- Beta-Blocker Heart Attack Trial (BHAT) Start of enrollment: 1977 Sep 01
Publications & Presentations
PubMed
- 8 citationsAssessing Prolongation of the Corrected QT Interval with Bedaquiline and Delamanid Coadministration to Predict the Cardiac Safety of Simplified Dosing Regimens.Lénaïg Tanneau, Mats O Karlsson, Susan L Rosenkranz, Yoninah S Cramer, Justin Shenje
Clinical Pharmacology and Therapeutics. 2022-10-01 - 46 citationsQT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.Kelly E. Dooley, Susan L. Rosenkranz, Francesca Conradie, Laura Moran, Richard Hafner
The Lancet. Infectious Diseases. 2021-02-12 - 5 citationsA Thorough QT/QTc Study With Laquinimod, a Novel Immunomodulator in Development for Multiple Sclerosis and Huntington Disease.Ofer Spiegelstein, Dorit Mimrod, Laura Rabinovich, Eli Eyal, Craig R Sprenger
Clinical Pharmacology in Drug Development. 2019-01-01
Professional Memberships
- Member
